Holen Sie sich die Stockscreener-App
5.54
1.77%
-0.10
Handel nachbörslich:
5.40
-0.14
-2.53%
Nuwellis Inc Aktie (NUWE) Neueste Nachrichten
Nuwellis outlines Q3 recovery and strategic shift after resolving $400,000 back order - MSN
Nuwellis, Inc. to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech - The Manila Times
Medical Technology Company Nuwellis to Showcase Fluid Management Solutions at Webull Investor Conference - Stock Titan
Nuwellis 2025 Q2 Earnings Net Loss Widens Despite EPS Improvement - AInvest
What makes Nuwellis Inc. stock price move sharplyWeekly Profit Analysis & Low Risk High Reward Trade Ideas - newsyoung.net
Nuwellis Inc (NUWE) Q2 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue Challenges - Yahoo Finance
Nuwellis, Inc. Reports Q2 2025 Financial Results - TipRanks
Does Nuwellis Inc. stock benefit from AI growth2025 Price Momentum & Long-Term Safe Investment Plans - thegnnews.com
Nuwellis, Inc. Q2 2025: Unpacking Key Contradictions in Revenue, Clinical Trials, and Outpatient Expansion - AInvest
Transcript : Nuwellis, Inc., Q2 2025 Earnings Call, Aug 14, 2025 - MarketScreener
Nuwellis Inc. Shows Support at Fibonacci LevelJuly 2025 Technicals & Reliable Intraday Trade Plans - sundaytimes.kr
Earnings call transcript: Nuwellis Q2 2025 sees revenue drop, stock dips By Investing.com - Investing.com Nigeria
Earnings call transcript: Nuwellis Q2 2025 sees revenue drop, stock dips - Investing.com
Nuwellis: A High-Risk Gamble in a Competitive Medical Tech Landscape? - AInvest
Nuwellis, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights - MarketScreener
Nuwellis Expands Pediatric Care Network to 47 Centers Despite Q2 Revenue Challenges - Stock Titan
Nuwellis to Report Q2 2025 Financial Results on August 12, 2025 - AInvest
Nuwellis Q2 2025 Earnings Call Transcript - MarketBeat
What are the future prospects of Nuwellis Inc.Weekly Return Focused Picks - newsyoung.net
Nuwellis NUWE 2025Q2 Earnings Preview Upside Potential on Strategic Healthcare Partnerships - AInvest
Nuwellis Triggers MACD Death Cross, KDJ Death Cross, Bearish Marubozu on 15min Chart - AInvest
Can Nuwellis Inc. recover in the next quarter5-Year Price Trend Summary and Analysis - Newser
Using fundamentals and technicals on Nuwellis Inc.Free Daily Profit Focused Stock Screener - Newser
Volume spikes in Nuwellis Inc. stock – what they meanFree Early Entry Tips With Low Risk Zone - Newser
Analyzing drawdowns of Nuwellis Inc. with statistical toolsFree Real Time Stock Movement Analysis - Newser
Is Nuwellis Inc. stock bottoming outRisk Aware Swing Trade Analysis Insights - Newser
How institutional ownership impacts Nuwellis Inc. stockProfitable Trading Blueprint with Entry Zones - Newser
Certain Stock Options of Nuwellis, Inc. are subject to a Lock-Up Agreement Ending on 9-AUG-2025. - MarketScreener
Can Nuwellis Inc. rally from current levelsEquity Signal Recap With Long-Term Summary - Newser
Nuwellis Inc. stock daily chart insightsTrade Setup Builder with Custom Alerts - Newser
Tick level data insight on Nuwellis Inc. volatilityFree Reliable Investment Entry Point Signals - Newser
Detecting price anomalies in Nuwellis Inc. with AIConservative Equity Setup with Signal Analysis - Newser
Institutional scanner results for Nuwellis Inc.3-Year Equity Summary With Setup Insights - Newser
How to use Fibonacci retracement on Nuwellis Inc.Long Term Stock Growth Plan Suggestions - Newser
Nuwellis Exits International Ops to Focus on U.S. Market Growth - AInvest
Nuwellis to exit international operations to accelerate US revenue growth and strategic focus - MarketScreener
Nuwellis' Strategic Realignment: Operational Discipline Fuels Growth in High-Demand U.S. Medical Tech Markets - AInvest
Nuwellis exits international operations to focus on U.S. market growth - Investing.com
Nuwellis to Exit International Operations to Accelerate U.S. Revenue Growth and Strategic Focus - The Manila Times
Nuwellis to exit international operations, focus on US market. - AInvest
Nuwellis Exits International Operations to Focus on US Market - AInvest
Nuwellis to Exit International Operations to Accelerate U.S. Rev - GuruFocus
Is Nuwellis Inc. forming a reversal patternFree AI Based High Gain Watchlist Scanner - Newser
Nuwellis Achieves Milestone in Outpatient Aquadex SmartFlow Therapy Under New CMS Code - AInvest
Nuwellis Postpones Q2 Earnings Release and Conference Call to August 14 - AInvest
Nuwellis postpones Q2 earnings release, conference call - TipRanks
Nuwellis Inc (NUWE) Stock: A Year of Highs and Lows in the Market - investchronicle.com
Nuwellis Postpones Second Quarter 2025 Earnings Release and Conference Call to August 14, 2025 - The Manila Times
Nuwellis Postpones Second Quarter 2025 Earnings Release and Conf - GuruFocus
Nuwellis Postpones Q2 Earnings Release, Conference Call - AInvest
Why Did Nuwellis Plunge 23.9% Ahead of Earnings? - AInvest
Why Nuwellis Inc. stock attracts strong analyst attentionShort Term Buy Zone Stock Alerts Signal Entry - metal.it
Nuwellis Announces the First Successful Outpatient Application of the Aquadex Smartflow® System Under New CMS Code - The Manila Times
Nuwellis Expands Aquadex Treatment to Outpatient Setting with 4x Higher Reimbursement Rate - Stock Titan
Nuwellis Plunges 10.89% Amid Clinical Trial Termination - AInvest
Is Nuwellis Inc. stock reversal real or fakeFree Stock Selection With High Accuracy - Newser
Press Release: Nuwellis Stockholders Approve All Proposals at Special Meeting - 富途牛牛
Nuwellis shareholders approve stock increase and reverse split at special meeting - Investing.com Canada
Nuwellis Approves Stock Proposals at Special Meeting - TipRanks
Nuwellis, Inc. Stockholders Approve Key Proposals to Enhance Financial Flexibility and Support Strategic Growth - Quiver Quantitative
PAMT names CFO Lance Stewart as CEO; 100k RSU incentive grant | NUWE SEC FilingForm 8-K - Stock Titan
Nuwellis Stockholders Approve All Proposals at Special Meeting - Yahoo Finance
Nuwellis Plummets 24.4% Amid Sector Turmoil: What's Driving the Bloodbath in MedTech? - AInvest
1.74%
0.24%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):